Pipeline

Genta has built a broad portfolio of proprietary products in various stages of clinical development. The Company’s lead compound, Genasense® (oblimersen sodium) Injection, has been studied in over 2300 patients with a wide variety of tumor types. At Genta, we are aggressively leveraging our expertise in clinical oncology research by expanding and diversifying our R&D pipeline.

If you would like more information on Genta products, please contact medinfo@genta.com.